AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01111474 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Laser
Description: This process was conducted three times with an interval of 48 hours between applications, according to laser's manufacturer advice Clean Line Easy Laser - LILT®, Clean Line Easy Laser Doctor Dental Products Industry LTDA, BRA). For dentin hypersensitivity, the application of 1Joule/cm\^2 is recommended for eight seconds at three points along the dental neck, using the infrared wavelength (795nm).
Study NCT01690312 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil
Description: On Day 1 and Day 15, participants will receive a 2-week supply of study supplements and will be instructed to consume 4 capsules per day. Each capsule contains 1000 mg of fish oil \[620 mg of DHA and 150 mg of EPA\], providing a total daily dosage of 4000 mg of fish oil \[3080 mg of DHA+EPA\].
Study NCT01690312 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: On Day 1 and Day 15, participants will receive a 2-week supply of study supplements and will be instructed to consume 4 capsules per day. Each capsule contains 1000 mg of olive oil, providing a total daily dosage of 4000 mg of olive oil.
Study NCT03404830 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIT group, MICT group
Description: The HIIT program training:~5 minutes of heating will be done. The intervention will consist of a training in suspension (TRX) performing squats. The session will be divided into four four-minute intervals at an intensity of 90-95% of the maximum heart rate, followed by three-minute active rest intervals of 50-70%. This intensity will be assigned to each subject individually. After the training, there will be a return to calm of 10 minutes of exercises of joint range. There will be 2 weekly training, with three days between both training, for a period of 12 weeks.~The training of the MICT program:~5 minutes of heating will be done. Subsequently, participants will perform a squat training with the Suspension Training System (TRX) with an intensity close to 70% of their maximum heart rate maintained for 40 minutes. The session will conclude with a return to calm of 10 min of joint width and stretching.
Study NCT01793311 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: decaffeinated coffee
Description: contains caffeine 0.5-2 mg
Study NCT01793311 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: regular dose coffee
Description: contains 91.8 mg of caffeine
Study NCT01793311 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: high dose coffee
Description: contains 144 mg of caffeine
Study NCT03413657 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Increase in intrathoracic pressure
Description: Will transiently increase intrathoracic pressure for 60 seconds and monitor for changes in hemodynamics during this time.
Study NCT02090959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ataluren
Description: Ataluren will be administered per the dose and schedule specified in the arm.
Study NCT03507660 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: verbal instruction
Description: Verbal instruction for pelvic floor contraction will be given to participants. Ultrasound examination will be conducted to asses urinary bladder displacement being a marker for pelvic floor muscle function.
Study NCT04617210 — intervention group
Intervention type: OTHER
Intervention: Neurocognitive tests and blood taking
Description: Battery of neurocognitive tests and questionnaires: MoCA, PHQ-9, Falls History, FIFE, STOPBANG, Nutritional Survey, CANTAB, Insomnia Severity Index, Bristol Activities of Daily Living Scale, NuDESC, 3D-CAM. Blood taking.
Study NCT00914264 — intervention group
Intervention type: DEVICE
Intervention: continuous positive airway pressure
Description: CPAP with adequate pressure for 1 day, 3 \& 12 months
Study NCT04220697 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electroencephalography (EEG)
Description: recording of resting state EEG using 64 surface electrodes
Study NCT04220697 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaires
Description: Hospital Anxiety Depression Scale (HADS) Neuropathic Pain questionnaire (DN4) Brief Pain Inventory (BPI) Fatigue Assessment Scale (FAS)
Study NCT04220697 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high frequency electrical stimulation of the forearm skin (HFS)
Description: HFS consists of transcutaneous electrical stimuli delivered as 42 Hz trains (pulse width: 2 ms) lasting 1 s. The trains are repeated 12 times. Each train is separated by 10 seconds.
Study NCT04220697 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cutaneous mechanical pinprick stimulation
Description: Mechanical pinprick stimuli will be applied manually by the operator on the skin using a mechanical stimulator (maximum weight 128 mN).
Study NCT02207881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VDO gel
Description: VDO gel
Study NCT02207881 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo gel
Study NCT01610141 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genotype-guided warfarin dosing
Description: Applying a Pharmacogenetic-guided warfarin dosing algorithm derived from Chinese to determine the daily maintenance dose of warfarin, based on clinical factors (age, sex, body surface area, etc.), and VKORC1, CYP2C9 and CYP4F2 genotypes, to individualize the dosing of warfarin.
Study NCT01610141 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-genotype guided warfarin dosing
Description: A Empiric fixed warfarin dose of 3 mg/day was given to the patients for at least 3 days. Following doses were adjusted according to the INR measurement.
Study NCT00762970 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 1
Description: Investigational soft contact lens with asperic optical design to control myopia progression.
Study NCT00762970 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 2
Description: Investigational soft contact lens with asperic optical design to control myopia progression.
Study NCT00762970 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Lens
Description: Spectacle Lenses.
Study NCT03133325 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: GP0045
Description: Hyaluronic acid gel
Study NCT03133325 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Restylane Lyft Lidocaine
Description: Hyaluronic acid gel
Study NCT00624923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salsalate
Description: Salsalate, 500 mg, seven tablets daily by mouth, divided into two doses, for 30 months
Study NCT00624923 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to Salsalate, seven tablets daily by mouth, divided into two doses, for 30 months
Study NCT00549809 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent mandatory ventilation (IMV) and synchronous IMV
Description: Patients divided to receive two different modes of mechanical ventilation.
Study NCT00666679 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: mometasone
Description: mometasone (inhalation powder, 220 mcg once-daily, for approximately 6 weeks)
Study NCT00666679 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: montelukast
Description: montelukast (inhalation powder, 1 mg once-daily, for approximately 2 weeks)
Study NCT00666679 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo (unspecified)
Description: Placebo (Placebo once-daily, for approximately 2 weeks)
Study NCT04261491 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: scaling and root planing
Description: scaling and root planing
Study NCT04020705 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Citicoline eye drops (OMK1)
Description: (OMK1) will be prescribed in the dosage of 1 drop 3 times a day
Study NCT04020705 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: hypromellose based ocular lubricant
Description: will be prescribed in the dosage of 1 drop 3 times a day
Study NCT03271021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FMX101
Description: FMX101, 4% minocycline foam
Study NCT03271021 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Foam
Description: Vehicle Foam
Study NCT02162589 — intervention group
Intervention type: PROCEDURE
Intervention: POEM
Description: Per oral endoscopic myotomy
Study NCT01548378 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: NL003
Description: Day 0: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 14: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 28: 8mg of NL003 (32 injections of 0.5ml of NL003)
Study NCT01548378 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: NL003
Description: Day 0: 6mg of NL003 (24 injections of 0.5ml of NL003) and 4ml normal saline(8 injections) Day 14: 6mg of NL003 (24 injections of 0.5ml of NL003) and 4ml normal saline(8 injections) Day 28: 6mg of NL003 (24 injections of 0.5ml of NL003) and 4ml normal saline(8 injections)
Study NCT01548378 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: NL003
Description: Day 0: 4mg of NL003 (16 injections of 0.5ml of NL003) and 8ml normal saline(16 injections) Day 14: 4mg of NL003 (16 injections of 0.5ml of NL003) and 8ml normal saline(16 injections) Day 28: 4mg of NL003 (16 injections of 0.5ml of NL003) and 8ml normal saline(16 injections)
Study NCT01548378 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Day 0: 16ml of Normal Saline (32 injections ) Day 14: 16ml of Normal Saline (32 injections ) Day 28: 16ml of Normal Saline (32 injections )
Study NCT03549533 — intervention group
Intervention type: OTHER
Intervention: samples of sperm
Description: As in the usual practice during artificial insemination a samples of sperm will be collected and analyzed.
Study NCT02354508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide LAR
Description: Pasireotide 40 mg and 60 mg. Pasireotide 20 mg which was allowed for dose decrease in case of adverse event.
Study NCT04125732 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdVEGFXC1
Description: AdVEGFXC1 at one of 4 doses
Study NCT02743377 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain PET Imaging with 11C Rolipram
Description: Brain PET Imaging, single scan, with 11C Rolipram 20 mCi given intravenously at the start of the scan
Study NCT02743377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Whole Body PET Baseline with 11C Rolipram
Description: Whole Body Baseline PET Imaging, single scan, with 11C Rolipram 20 mCi given intravenously at the start of the scan
Study NCT02743377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Whole Body PET Blocked with Roflumilast
Description: Whole Body PET Imaging scan after blockade with Roflumilast 500 mcg PO, given 1-2 hours prior to start of scan
Study NCT04641494 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Conjugated linoleic acid
Description: CLA Mixture capsule (50:50, c9, t11-CLA: t10, c12-CLA)
Study NCT04641494 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: High oleic acid safflower oil capsules
Study NCT03183700 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self sampling device
Description: The investigators will allocate randomly the women to two different self sampling devices differing in having or not a preservative buffer
Study NCT03183700 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cervical ThinPrep sampling
Description: Women are inviated with a standard invitation letter to perform cervical ThinPrep sampling at the clinic on a pre-fixed date
Study NCT01444573 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: implantable continuous monitor
Description: The Reveal XT was implanted in the parasternal area of the chest. The requirement for defining the exact final position was an R-wave amplitude ≥0.4 mV assessed through the Vector Check.
Study NCT04500431 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Targeting CD269 chimeric antigen receptor engineered T cells
Description: Targeting CD269 chimeric antigen receptor engineered T cells, single infusion intravenously
Study NCT02942238 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CME
Description: the group underwent laparoscopic right hemicolectomy with CME. In CME group, in addition to D2 dissection, the whole mesocolon, from ascending colon to right half transverse colon, as well as the central lymph nodes should be entirely removed.~Intervention: Procedure: Complete mesocolic excision (CME)
Study NCT02942238 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: D3
Description: the group underwent laparoscopic right hemicolectomy with D3 lymph node dissection. In D3 group, the mesocolon should be removed and the dissection involves the paracolon and intermediate lymph nodes,including No.6 lymph node, which along the feeding vessels.~Intervention: Procedure: D3 radical operation
Study NCT01059123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: 50 mg/kg/24H ; Per Os ; 3 times/day 6 days
Study NCT01059123 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: 50 mg/kg/24H in I.V. ; 3 times/day ; up to apyrexia then amoxicillin ; 50 mg/kg/24H ; Per Os ; 3 times/day up to day 14.
Study NCT01955889 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Health Technology
Study NCT01955889 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching & Strengthening Exercises
Study NCT01955889 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stretching & Strengthening Exercises
Study NCT01955889 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Walking with Pedometer
Study NCT01955889 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking with Pedometer
Study NCT02878681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: 0.5 mg intravitreal injections
Study NCT02878681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: 2 mg intravitreal injections
Study NCT00582686 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ORIF of Calcaneus with bone grafting
Description: The calcaneus fracture will be surgically repaired with open reduction and internal fixation (ORIF) and Tricortical Iliac Crest bone grafting
Study NCT02285465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3700
Description: Oral
Study NCT02285465 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study NCT00986674 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cixutumumab
Description: Given IV
Study NCT00986674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT00986674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study NCT00986674 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV
Study NCT01927029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Vaginal progesterone gel 180mg/daily is given from second trimester (18 to 24 weeks) until 34 weeks.
Study NCT01927029 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02564874 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discretionary calorie source
Description: We are assigning participants randomly to either of two different sources of discretionary calories (savory snacks or sugary beverages)
Study NCT04684602 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PrimePro™/ PrimeMSK™
Description: Injection via condition specific route of administration.
Study NCT01951963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Study NCT01951963 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Study NCT03523988 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen gel capsule
Study NCT03523988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen gel capsule
Study NCT03523988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Ibuprofen gel capsule
Study NCT03523988 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen gel capsule
Study NCT01958164 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Actilyse
Description: Actilyse 2mg/2ml will be given if the CVAD has not been restored at time 120min.
Study NCT01958164 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline solution
Description: Instil Saline solution 2 ml into the disfunctional CVAD once at time O only for patients enrolled in Group II
Study NCT01958164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Actilyse
Description: Instil Actilyse 2 mg/ 2 ml into the dysfunctional CVAD at time O.
Study NCT01958164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Actilyse
Description: Second dose of Actilyse 2mg/2ml will be given if CVAD has not been restored at time 120min.
Study NCT02546388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indium-111 Pentreotide
Study NCT01468831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: 100 mg of minocycline in a pink opaque capsule
Study NCT01468831 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pill with inactive ingredients in a pink opaque capsule
Study NCT01468831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 1.25 mg bevacizumab injection
Study NCT01468831 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bevacizumab
Description: 1.25 mg bevacizumab injection
Study NCT02768870 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Harpoon Artificial ePTFE Chords
Description: It is anticipated that use of the Harpoon device could achieve similar outcomes to open cardiac surgery while decreasing the invasiveness of mitral valve repair.
Study NCT04388397 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arteriovenous Grafts
Description: Arteriovenous fistulae (AVF) are considered the main access for hemodialysis (HD). Arteriovenous grafts (AVGs) are an alternative access modality in patients with exhausted native venous access. Immediate-access arteriovenous grafts (IAAVGs) is a new modality in which dialysis can be started immediately to avoid complications of central venous catheters.
Study NCT04388397 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arteriovenous Grafts
Description: Arteriovenous fistulae (AVF) are considered the main access for hemodialysis (HD). Arteriovenous grafts (AVGs) are an alternative access modality in patients with exhausted native venous access. Immediate-access arteriovenous grafts (IAAVGs) is a new modality in which dialysis can be started immediately to avoid complications of central venous catheters.
Study NCT04459247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vit D
Description: Oral liquid formulation of 60000 IU
Study NCT02963610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide is a thalidomide analogue with immunomodulatory, anti-angiogenic, and antineoplastic effects. It is administered as a pill taken orally. It has completed phase III study evaluation and has FDA indications for use in certain patients with multiple myeloma, myelodysplastic syndrome, and mantle cell lymphoma.
Study NCT02963610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a humanized IgG4 monoclonal antibody which targets the PD-1 receptor, thus inhibiting the interaction between PD-1 and its ligands, PD-L1 and PD-L2 respectively. It is administered as an IV infusion. This drug has several studies in patients with solid tumors and currently has an FDA indication for use in patients with melanoma and non-small cell lung cancer.
Study NCT01935180 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy Cap
Description: 4mm transparent cap (Olympus) mounted to the tip of a colonoscope.
Study NCT06004947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCX168
Description: Administered orally.
Study NCT06004947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Administered orally.
Study NCT06004947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Administered orally.
Study NCT06004947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Administered orally.
Study NCT06004947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Administered orally.